Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | MTOR | P42345 | 3/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | GAK | O14976 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17128116 | 1.00 | HDAC6 (0.43) | HDAC6AOC3MTORPIK3CAMAPT | |
| SCHEMBL20796706 | 1.00 | HDAC6 (0.43) | HDAC6AOC3MTORPIK3CAMAPT | |
| SCHEMBL20796804 | 1.00 | HDAC6 (0.43) | HDAC6AOC3MTORPIK3CAMAPT | |
| SCHEMBL18539060 | 0.84 | CHRM4 (0.32) | KMT2AGAA | |
| SCHEMBL20606546 | 0.81 | WDR5 (0.38) | GAK | |
| SCHEMBL20606305 | 0.81 | WDR5 (0.38) | GAK | |
| SCHEMBL20606306 | 0.81 | WDR5 (0.38) | GAK | |
| SCHEMBL18128074 | 0.81 | MTOR (0.31) | MTORPIK3CA | |
| SCHEMBL22733710 | 0.80 | MTOR (0.38) | MTORPIK3CA | |
| SCHEMBL20605945 | 0.80 | CHRM4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2025-04-01 | — | — | US | disclosed |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | FACIT INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-3423451-B1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | PROPELLON THERAPEUTICS INC (CA) | 2022-08-17 | — | — | EP | disclosed |
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | Propellon Therapeutics Inc. (CA) | 2022-05-03 | — | — | US | disclosed |
| US-11225655-B2 | Bi-functional complexes and methods for making and using such complexes | NUEVOLUTION A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| EP-3540059-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2019-09-18 | — | — | EP | disclosed |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-04-18 | — | — | US | disclosed |
| EP-3423451-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | Propellon Therapeutics Inc. (CA) | 2019-01-09 | — | — | EP | disclosed |
| EP-2558577-B1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION AS (DK) | 2018-12-12 | — | — | EP | disclosed |
| US-20130281324-A1 | BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2013-10-24 | — | — | US | disclosed |
| EP-2558577-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | Nuevolution A/S (DK) | 2013-02-20 | — | — | EP | disclosed |
| WO-2011127933-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319299-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | HDAC6 75/4885AOC3 4636/4885MTOR 1559/4885 |
| US-12264147-B2 | Substituted carboxamides as inhibitors of WDR5 protein-protein binding | WDR5, WDR82, WDR1 | HDAC6 75/4885AOC3 4636/4885MTOR 1559/4885 |
| US-20190112290-A1 | INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HDAC6 201/4885AOC3 4705/4885MTOR 1318/4885 |
| US-20230219926-A1 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING | WDR5, WDR82, WDR1 | HDAC6 75/4885AOC3 4636/4885MTOR 1559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.